The Minister of Science and Innovation, Diana Morant, has indicated that the vaccine against Covid-19 from the Catalan company Hipra, whose clinical trials were approved yesterday by the Spanish Agency for Medicines and Health Products (AEMPS), can begin to be marketed “early 2022”.
In an interview with the 24 Hours channel, Morant stressed that it is “a very important decisive step” for Spanish science. “It is the first vaccine developed entirely in Spain that is going to make the leap to the clinical trial in humans. We started with 20 research projects in vaccines and this one right now is the one that is most advanced “, he highlighted.
Regarding the company’s forecasts, the minister pointed out that “in her expectations it would be start producing doses in October so that by the end of the year it would be produced and be able to market it at the beginning of 2022 “.
Compared to the vaccines already approved, Morant has assured that Hipra’s “presents several improvements”: “It has been designed taking into account different variants of the coronavirus, shows a very good immune response so far in the preclinical trial and a third quite remarkable characteristic is that it does not need to be frozen for distribution. All this makes it a different and improved vaccine in some respects than those that already exist. “
The Minister of Science has rejected that the lack of official funding has been one of the reasons for the ‘delay’ of a ‘Spanish’ vaccine. “It has not been the reason pointed out by scientists or the CSIC or private industries. They have had the support and advice of the European Union. Everything that has been asked of us has been provided by the Government of Spain“, has riveted.